Tianjin Biopharmaceutical Innovation Park To Start Operation In April
This article was originally published in PharmAsia News
China's biopharmaceutical international innovation park, sited in Tianjin Economic-Technological Development Area, has completed its phase one construction and will go into operation in April. To date, the park has received more than 170 domestic and overseas applications of R&D projects; it has already confirmed the location of four industrial companies with investment of over RMB100 million ($14.61 million) each. Tianjin International Biomedical Research Institute, the park's core component, will by year end establish a series of technical platforms including its clinical trial center, drug analysis and testing center, and information center. By the end of 2010, the park will be a world-class biopharmaceutical R&D base with more than 100 R&D teams and 1,000 people. (Click here for more - Chinese Language)
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.